Skip to main content
GENPHARMASEC LIMITED logo

GENPHARMASEC LIMITED — Investor Relations & Filings

Ticker · 531592 ISIN · INE861N01036 LEI · 98450071I6563864E725 BSE.NS Wholesale and retail trade
Open in API
Filings indexed 5 across all filing types
Latest filing 2026-05-23 Report Publication Anno…
Country IN India
Listing BSE.NS 531592

About GENPHARMASEC LIMITED

https://www.genpharmasec.com

Genpharmasec Limited is a specialized enterprise focused on the procurement, marketing, and distribution of pharmaceutical products, medical equipment, and diagnostic solutions. The company operates as a strategic intermediary, bridging the gap between global manufacturers and local healthcare providers. Its core portfolio includes active pharmaceutical ingredients (APIs), specialty chemicals, and advanced diagnostic machinery used in clinical laboratories and hospitals. By leveraging a robust supply chain and technical expertise, Genpharmasec facilitates the availability of critical medical technologies and high-quality chemical components. The firm emphasizes quality assurance and regulatory compliance, catering to a diverse clientele that includes pharmaceutical manufacturers, diagnostic centers, and healthcare institutions. Its business model centers on identifying niche market requirements and providing integrated sourcing and distribution services.

Recent filings

Filing Released Lang Actions
Newspaper Publication of Audited Financial Result for the quarter and year ended 31st March, 2026.
Report Publication Announcement Classification · 82% confidence The document is a short exchange with BSE Limited under SEBI LODR Regulations 30 & 47, stating that the audited standalone and consolidated financial results for the quarter & year ended 31 March 2026 have been published in newspapers and that an extract is attached. It does not itself contain the full financial statements but merely announces and encloses the newspaper extract. Under the “menu vs meal” rule, this is an announcement of report publication rather than the report itself.
2026-05-23 English
Statement of deviation or variation in the use of proceeds of Rights issue for the Quarter ended 31st March, 2026.
Capital/Financing Update Classification · 90% confidence The document is a quarterly ‘‘Statement of deviation or variation in the use of proceeds of Rights Issue’’ filed under Regulation 32 of SEBI (LODR) to the stock exchange. It provides details on how funds raised via a rights issue have been applied and confirms no deviations. This is a periodic update on fundraising proceeds and their utilisation, fitting the definition of a Capital/Financing Update rather than a full financial report or an earnings release.
2026-05-21 English
Audited Standalone & Consolidated Financial Results of the company for the Quarter and Financial year Ended 31st March, 2026.
Audit Report / Information Classification · 82% confidence The document is a SEBI LODR regulation 30 & 33 disclosure of audited financial results for the quarter and year ended March 31, 2026. It includes the Board meeting outcome approving the standalone & consolidated audited results along with the Auditor’s Report containing an unmodified opinion and details of the audit engagement. This is not a full annual report (10-K) nor just an earnings highlight. It provides the actual audit report and detailed financial statements, fitting the “Audit Report / Information” (AR) definition.
2026-05-21 English
Outcome of the Meeting of Board of Directors held on Thursday, May 21, 2026.
Interim / Quarterly Report Classification · 86% confidence The document is a compliance filing under Regulations 30 and 33 of India’s SEBI Listing Obligations, detailing the Board’s approval of audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. It includes full financial statements (Results, Statement of Assets & Liabilities, Cash Flows, Segment Report) and the Auditors’ Reports rather than merely announcing that a report has been published. It is not just a highlights‐only earnings release, nor a proxy statement or director change notice. This corresponds to a substantive interim/quarterly financial report (IR) in our taxonomy. FY 2026
2026-05-21 English
Genpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 ,inter alia, to consider and approve 1. To consider, approve & take ....
Regulatory Filings Classification · 85% confidence The document is an exchange filing notifying BSE Limited of a scheduled Board of Directors meeting to approve audited financial results under SEBI Listing Regulations. It does not contain the financial results themselves nor announce a change in board membership or management, but is a routine regulatory/compliance notice. This falls under the general “Regulatory Filings” category (RNS).
2026-05-13 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.